-
The one‐carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation Mol. Oncol. (IF 6.6) Pub Date : 2024-03-27 Petra Marttila, Nadilly Bonagas, Christina Chalkiadaki, Hannah Stigsdotter, Korbinian Schelzig, Jianyu Shen, Crystal M. Farhat, Amber Hondema, Julian Albers, Elisée Wiita, Azita Rasti, Ulrika Warpman Berglund, Ana Slipicevic, Oliver Mortusewicz, Thomas Helleday
The one‐carbon metabolism enzyme bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase 2 (MTHFD2) is among the most overexpressed proteins across tumors and is widely recognized as a promising anticancer target. While MTHFD2 is mainly described as a mitochondrial protein, a new nuclear function is emerging. Here, we observe that nuclear MTHFD2 protein levels and association with chromatin
-
-
Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells Mol. Oncol. (IF 6.6) Pub Date : 2024-03-23 Anita G. Kansy, Ramy Ashry, Al‐Hassan M. Mustafa, Abdallah M. Alfayomy, Markus P. Radsak, Yanira Zeyn, Matthias Bros, Wolfgang Sippl, Oliver H. Krämer
Mammalian cells replicate ~ 3 × 109 base pairs per cell cycle. One of the key molecules that slows down the cell cycle and prevents excessive DNA damage upon DNA replication stress is the checkpoint kinase ataxia‐telangiectasia‐and‐RAD3‐related (ATR). Proteolysis‐targeting‐chimeras (PROTACs) are an innovative pharmacological invention to molecularly dissect, biologically understand, and therapeutically
-
Tumour immunogenicity goes with the (mitochondrial electron) flow Mol. Oncol. (IF 6.6) Pub Date : 2024-03-23 Asma Ahmed, Stephen W. G. Tait
Mitochondrial metabolism and electron transport chain (ETC) function are essential for tumour proliferation and metastasis. However, the impact of ETC function on cancer immunogenicity is not well understood. In a recent study, Mangalhara et al. found that inhibition of complex II leads to enhanced tumour immunogenicity, T‐cell‐mediated cytotoxicity and inhibition of tumour growth. Surprisingly, this
-
Minimally invasive biopsy‐based diagnostics in support of precision cancer medicine Mol. Oncol. (IF 6.6) Pub Date : 2024-03-23 Bo Franzén, Gert Auer, Rolf Lewensohn
Precision cancer medicine (PCM) to support the treatment of solid tumors requires minimally invasive diagnostics. Here, we describe the development of fine‐needle aspiration biopsy‐based (FNA) molecular cytology which will be increasingly important in diagnostics and adaptive treatment. We provide support for FNA‐based molecular cytology having a significant potential to replace core needle biopsy
-
Postbiotics of Lacticaseibacillus paracaseiCECT 9610 and Lactiplantibacillus plantarumCECT 9608 attenuates store‐operated calcium entry and FAK phosphorylation in colorectal cancer cells Mol. Oncol. (IF 6.6) Pub Date : 2024-03-22 Alvaro Macias‐Diaz, Jose J. Lopez, Maria Bravo, Isaac Jardín, Waldo Luis Garcia‐Jimenez, Francisco J. Blanco‐Blanco, Rosario Cerrato, Juan A. Rosado
-
Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD‐L1‐expressing head and neck cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-03-21 Jeon Yeob Jang, Bok‐Soon Lee, Mei Huang, Chorong Seo, Ji‐Hye Choi, Yoo Seob Shin, Hyun Goo Woo, Chul‐Ho Kim
-
Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti‐tumor efficacy Mol. Oncol. (IF 6.6) Pub Date : 2024-03-20 Yasmin Yu, Madhumita Bogdan, Muhammad Zaeem Noman, Santiago Parpal, Elisabetta Bartolini, Kris Van Moer, Simone Caroline Kleinendorst, Kristine Bilgrav Saether, Lionel Trésaugues, Camilla Silvander, Johan Lindström, Jodi Simeon, Mary Jane Timson, Hikmat Al‐Hashimi, Bryan D. Smith, Daniel L. Flynn, Andrey Alexeyenko, Jenny Viklund, Martin Andersson, Jessica Martinsson, Katja Pokrovskaja Tamm, Angelo
-
Acetylated KHSRP impairs DNA‐damage‐response‐related mRNA decay and facilitates prostate cancer tumorigenesis Mol. Oncol. (IF 6.6) Pub Date : 2024-03-19 Haihua Yuan, Renjie Cai, Biying Chen, Qian Wang, Mengting Wang, Junyi An, Weishu An, Ye Tao, Jianxiu Yu, Bin Jiang, Yanjie Zhang, Ming Xu
-
Plasma membrane SK2 channel activity regulates migration and chemosensitivity of high‐grade serous ovarian cancer cells Mol. Oncol. (IF 6.6) Pub Date : 2024-03-14 Olivier Romito, Aude Lemettre, Aurélie Chantôme, Ophélie Champion, Noémie Couty, Lobna Ouldamer, Nadine Hempel, Mohamed Trebak, Caroline Goupille, Marie Potier‐Cartereau
-
Transcriptome‐wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-03-12 Elisa Mariella, Gaia Grasso, Martina Miotto, Kristi Buzo, Nicole Megan Reilly, Pietro Andrei, Pietro Paolo Vitiello, Giovanni Crisafulli, Sabrina Arena, Giuseppe Rospo, Giorgio Corti, Annalisa Lorenzato, Carlotta Cancelliere, Ludovic Barault, Giulia Gionfriddo, Michael Linnebacher, Mariangela Russo, Federica Di Nicolantonio, Alberto Bardelli
-
From the creation of the European research area in 2000 to a Mission on cancer in Europe in 2021‐lessons learned and implications Mol. Oncol. (IF 6.6) Pub Date : 2024-03-12 Julio Celis, Ulrik Ringborg
-
Unlocking the potential of tumor‐derived DNA in urine for cancer detection: methodological challenges and opportunities Mol. Oncol. (IF 6.6) Pub Date : 2024-03-11 Birgit M. M. Wever, Renske D. M. Steenbergen
-
RIP140 regulates transcription factor HES1 oscillatory expression and mitogenic activity in colon cancer cells Mol. Oncol. (IF 6.6) Pub Date : 2024-03-09 Nour Sfeir, Marilyn Kajdan, Stéphan Jalaguier, Sandrine Bonnet, Catherine Teyssier, Samuel Pyrdziak, Rong Yuan, Emilie Bousquet, Antonio Maraver, Florence Bernex, Nelly Pirot, Florence Boissière‐Michot, Audrey Castet‐Nicolas, Marion Lapierre, Vincent Cavaillès
-
Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-03-09 Manuel Rigon, Luciano Mutti, Michelangelo Campanella
-
The MYC–NFATC2 axis maintains the cell cycle and mitochondrial function in acute myeloid leukaemia cells Mol. Oncol. (IF 6.6) Pub Date : 2024-03-09 Shaun D. Patterson, Matthew E. Massett, Xu Huang, Heather G. Jørgensen, Alison M. Michie
-
-
Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy Mol. Oncol. (IF 6.6) Pub Date : 2024-03-08 Minmin Wang, Linzi Jia, Xiangpeng Dai, Xiaoling Zhang
-
Retraction: p53 loses grip on PIK3CA expression leading to enhanced cell survival during platinum resistance Mol. Oncol. (IF 6.6) Pub Date : 2024-03-04
The above article, published online on 29 April 2016 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Kevin Ryan, FEBS Press, and John Wiley and Sons Ltd. The retraction has been agreed due to several image duplications in Figures 4B,E,G, and 5C,D, and inconsistencies between tumour luminescence images and the quantification in Figure
-
Dual role of GRHL3 in bladder carcinogenesis depending on histological subtypes Mol. Oncol. (IF 6.6) Pub Date : 2024-03-02 Franziska C. Lammert, Julia Pannhausen, Erik Noetzel, Florian Friedland, Julia Wirtz, Yannick Herfs, Sophie Leypold, Lin Gan, Ralf Weiskirchen, Tician Schnitzler, Ruth Knüchel, Jochen Maurer, Danny D. Jonigk, Michael Rose, Nadine T. Gaisa
-
The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-03-02 Adi Alfandari, Dotan Moskovich, Avivit Weisz, Aviva Katzav, Debora Kidron, Mario Beiner, Dana Josephy, Aula Asali, Yael Hants, Yael Yagur, Omer Weitzner, Martin Ellis, Gilad Itchaki, Osnat Ashur‐Fabian
-
Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models Mol. Oncol. (IF 6.6) Pub Date : 2024-03-01 Tet Woo Lee, Dean C. Singleton, Julia K. Harms, Man Lu, Sarah P. McManaway, Amy Lai, Moana Tercel, Frederik B. Pruijn, Andrew M. J. Macann, Francis W. Hunter, William R. Wilson, Stephen M. F. Jamieson
-
Vitamin‐C‐dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest Mol. Oncol. (IF 6.6) Pub Date : 2024-03-01 Aiora Cenigaonandia‐Campillo, Ana Garcia‐Bautista, Anxo Rio‐Vilariño, Arancha Cebrian, Laura del Puerto, José Antonio Pellicer, José Antonio Gabaldón, Horacio Pérez‐Sánchez, Miguel Carmena‐Bargueño, Carolina Meroño, Javier Traba, María Jesús Fernandez‐Aceñero, Natalia Baños‐Herraiz, Lorena Mozas‐Vivar, Estrella Núñez‐Delicado, Jesús Garcia‐Foncillas, Óscar Aguilera
-
The CK1ε/SIAH1 axis regulates AXIN1 stability in colorectal cancer cells Mol. Oncol. (IF 6.6) Pub Date : 2024-02-29 Mengfang Yan, Zijie Su, Xiaoyi Pang, Hanbin Wang, Han Dai, Jiong Ning, Shanshan Liu, Qi Sun, Jiaxing Song, Xibao Zhao, Desheng Lu
-
Cancer cachexia: biomarkers and the influence of age Mol. Oncol. (IF 6.6) Pub Date : 2024-02-28 Julia Geppert, Maria Rohm
-
PIKFYVE inhibitors trigger interleukin‐24‐dependent cell death of autophagy‐dependent melanoma Mol. Oncol. (IF 6.6) Pub Date : 2024-02-28 Ajit Roy, Arup R. Chakraborty, Melvin L. DePamphilis
-
From monocyte‐derived macrophages to resident macrophages—how metabolism leads their way in cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-02-27 Ummi Ammarah, Andreia Pereira‐Nunes, Marcello Delfini, Massimiliano Mazzone
-
STING activator 2′3′‐cGAMP enhanced HSV‐1‐based oncolytic viral therapy Mol. Oncol. (IF 6.6) Pub Date : 2024-02-24 Patricia Angela Sibal, Shigeru Matsumura, Toru Ichinose, Itzel Bustos‐Villalobos, Daishi Morimoto, Ibrahim R. Eissa, Mohamed Abdelmoneim, Mona Alhussein Mostafa Aboalela, Nobuaki Mukoyama, Maki Tanaka, Yoshinori Naoe, Hideki Kasuya
-
Regulation and tumor‐suppressive function of the miR‐379/miR‐656 (C14MC) cluster in cervical cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-02-24 Sriharikrishnaa Srinath, Padacherri Vethil Jishnu, Vinay Koshy Varghese, Vaibhav Shukla, Divya Adiga, Sandeep Mallya, Sanjiban Chakrabarty, Krishna Sharan, Deeksha Pandey, Aniruddha Chatterjee, Shama Prasada Kabekkodu
-
MAP4K4 and WT1 mediate SOX6-induced cellular senescence by synergistically activating the ATF2–TGFβ2–Smad2/3 signaling pathway in cervical cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-02-21 Han Zheng, Mingchen Liu, Shu Shi, Hongxin Huang, Xingwen Yang, Ziheng Luo, Yarong Song, Qiang Xu, Tingting Li, Lixiang Xue, Fengmin Lu, Jie Wang
-
The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis Mol. Oncol. (IF 6.6) Pub Date : 2024-02-17 Kelly Conde-Pérez, Pablo Aja-Macaya, Elena Buetas, Noelia Trigo-Tasende, Mohammed Nasser-Ali, Soraya Rumbo-Feal, Paula Nión, Elsa Martín-De Arribas, Lara S. Estévez, Begoña Otero-Alén, José F. Noguera, Ángel Concha, Simón Pardiñas-López, Miguel Carda-Diéguez, Igor Gómez-Randulfe, Nieves Martínez-Lago, Susana Ladra, Luis M. A. Aparicio, Germán Bou, Álex Mira, Juan A. Vallejo, Margarita Poza
-
Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node Mol. Oncol. (IF 6.6) Pub Date : 2024-02-16 Rossella Scardaci, Ewa Berlinska, Pietro Scaparone, Sandra Vietti Michelina, Edoardo Garbo, Silvia Novello, David Santamaria, Chiara Ambrogio
-
Immunosuppressive role of BDNF in therapy‐induced neuroendocrine prostate cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-02-21 Yen‐Nien Liu, Wei‐Yu Chen, Ming‐Kun Liu, Hsiu‐Lien Yeh, Wei‐Hao Chen, Kuo‐Ching Jiang, Han‐Ru Li, Zi‐Qing Chen, Wan‐Hsin Wang, Wassim Abou‐Kheir, Yu‐Ching Wen
-
ITIH5 as a multifaceted player in pancreatic cancer suppression, impairing tyrosine kinase signaling, cell adhesion and migration Mol. Oncol. (IF 6.6) Pub Date : 2024-02-20 Jennifer Kosinski, Antonio Sechi, Johanna Hain, Sophia Villwock, Stefanie Anh Ha, Maximilian Hauschulz, Michael Rose, Florian Steib, Nadina Ortiz‐Brüchle, Lara Heij, Sanne L. Maas, Emiel P. C. van der Vorst, Thomas Knoesel, Annelore Altendorf‐Hofmann, Ronald Simon, Guido Sauter, Jan Bednarsch, Danny Jonigk, Edgar Dahl
-
An arms-race against resistance: leukemic stem cells and lineage plasticity Mol. Oncol. (IF 6.6) Pub Date : 2024-02-20 Alexander Waclawiczek, Aino-Maija Leppä, Simon Renders, Andreas Trumpp
-
TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling Mol. Oncol. (IF 6.6) Pub Date : 2024-02-15 Carlos Marugán, Natalia Sanz-Gómez, Beatriz Ortigosa, Ana Monfort-Vengut, Cristina Bertinetti, Ana Teijo, Marta González, Alicia Alonso de la Vega, María José Lallena, Gema Moreno-Bueno, Guillermo de Cárcer
-
PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects Mol. Oncol. (IF 6.6) Pub Date : 2024-02-15 Pratheesh Kumar Poyil, Abdul K. Siraj, Divya Padmaja, Sandeep Kumar Parvathareddy, Saravanan Thangavel, Khadija Alobaisi, Roxanne Diaz, Rafia Begum, Wael Haqawi, Saif S. Al-Sobhi, Fouad Al-Dayel, Khawla S. Al-Kuraya
-
IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review Mol. Oncol. (IF 6.6) Pub Date : 2024-02-09 Olfat Ahmad, Tahani Ahmad, Stefan M. Pfister
-
Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models Mol. Oncol. (IF 6.6) Pub Date : 2024-02-13 Federica Maione, Daniele Oddo, Federica Galvagno, Chiara Falcomatà, Marta Pandini, Marco Macagno, Valeria Pessei, Ludovic Barault, Chiara Gigliotti, Alessia Mira, Giorgio Corti, Simona Lamba, Chiara Riganti, Barbara Castella, Massimo Massaia, Roland Rad, Dieter Saur, Alberto Bardelli, Federica Di Nicolantonio
Serine/threonine-protein kinase B-raf (BRAF) mutations are found in 8–15% of colorectal cancer patients and identify a subset of tumors with poor outcome in the metastatic setting. We have previously reported that BRAF-mutant human cells display a high rate of protein production, causing proteotoxic stress, and are selectively sensitive to the proteasome inhibitors bortezomib and carfilzomib. In this
-
Recurrence/prognosis estimation using a molecularly positive surgical margin-based model calls for alternative curative strategies in pIIIA/N2 NSCLC Mol. Oncol. (IF 6.6) Pub Date : 2024-02-07 Li Li, Kewen He, Tao Zhou, Yang Xu, Jiaohui Pang, Qingxi Yu, Yongsheng Gao, Hongjin Shi, He Zhu, Mengke Li, Jinming Yu, Shuanghu Yuan
-
High FLT3 expression increases immune-cell infiltration in the tumor microenvironment and correlates with prolonged disease-free survival in patients with non-small cell lung cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-02-07 Łukasz Kuncman, Magdalena Orzechowska, Tomasz Milecki, Jakub Kucharz, Jacek Fijuth
-
Links between melanoma germline risk loci, driver genes and comorbidities: insight from a tissue-specific multi-omic analysis Mol. Oncol. (IF 6.6) Pub Date : 2024-02-03 Michael Pudjihartono, Evgeniia Golovina, Tayaza Fadason, Justin M. O'Sullivan, William Schierding
-
-
Genetic and non-genetic drug resistance: Darwin or Lamarck? Mol. Oncol. (IF 6.6) Pub Date : 2024-02-02 Mariangela Russo
-
Harmony in chaos: understanding cancer through the lenses of developmental biology Mol. Oncol. (IF 6.6) Pub Date : 2024-01-29 Jonas Van Lent, Arianna Baggiolini
-
Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-01-29 Julien Corné, Véronique Quillien, Florence Godey, Mathilde Cherel, Agathe Cochet, Fanny Le Du, Lucie Robert, Héloïse Bourien, Angélique Brunot, Laurence Crouzet, Christophe Perrin, Claudia Lefeuvre-Plesse, Véronique Diéras, Thibault De la Motte Rouge
-
Deciphering metabolic crosstalk in context: lessons from inflammatory diseases Mol. Oncol. (IF 6.6) Pub Date : 2024-01-26 Fenne W. M. Verheijen, Thi N. M. Tran, Jung-Chin Chang, Femke Broere, Esther A. Zaal, Celia R. Berkers
-
ASPM stabilizes the NOTCH intracellular domain 1 and promotes oncogenesis by blocking FBXW7 binding in hepatocellular carcinoma cells Mol. Oncol. (IF 6.6) Pub Date : 2024-01-26 Tze-Sian Chan, Li-Hsin Cheng, Chung-Chi Hsu, Pei-Ming Yang, Tai-Yan Liao, Hsiao-Yen Hsieh, Pei-Chun Lin, Wei-Chun HuangFu, Chih-Pin Chuu, Kelvin K. Tsai
-
Correction to: Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C Mol. Oncol. (IF 6.6) Pub Date : 2024-01-24
In the manuscript by Elin Thysell et al. [[1]], Figure legends for Supplementary Fig. S1 and Fig. S2 and the Supplementary file ‘Supplementary information_rev’ were missing but are now provided. Figure legends for Supplementary Fig. S1 and Fig. S2 should read as below: Figure S1. Associations between the metastasis subtypes A-C (MetA-C) and ETS gene fusion status. Mean fraction estimates of the MetA-C
-
Liprin-α1 contributes to oncogenic MAPK signaling by counteracting ERK activity Mol. Oncol. (IF 6.6) Pub Date : 2024-01-24 Henna Pehkonen, Artemis Filippou, Juho Väänänen, Iida Lindfors, Mira Vänttinen, Philipp Ianevski, Anne Mäkelä, Pauliina Munne, Juha Klefström, Sanna Toppila-Salmi, Reidar Grénman, Jaana Hagström, Antti A. Mäkitie, Piia-Riitta Karhemo, Outi Monni
-
STIM2 is involved in the regulation of apoptosis and the cell cycle in normal and malignant monocytic cells Mol. Oncol. (IF 6.6) Pub Date : 2024-01-17 Stefan Djordjevic, Raphaël Itzykson, Frédéric Hague, Delphine Lebon, Julien Legrand, Hakim Ouled-Haddou, Guillaume Jedraszak, Juliette Harbonnier, Louison Collet, Etienne Paubelle, Jean-Pierre Marolleau, Loïc Garçon, Thomas Boyer
-
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis Mol. Oncol. (IF 6.6) Pub Date : 2024-01-15 Tatsuo Sugawara, Ekaterina Nevedomskaya, Simon Heller, Annika Böhme, Ralf Lesche, Oliver von Ahsen, Sylvia Grünewald, Holly M. Nguyen, Eva Corey, Simon J. Baumgart, Victoria Georgi, Vera Pütter, Amaury Fernández-Montalván, James D. Vasta, Matthew B. Robers, Oliver Politz, Dominik Mumberg, Bernard Haendler
-
Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759 Mol. Oncol. (IF 6.6) Pub Date : 2024-01-12 Marc Pujalte-Martin, Amine Belaïd, Simon Bost, Michel Kahi, Pascal Peraldi, Matthieu Rouleau, Nathalie M. Mazure, Frédéric Bost
-
Enhancing therapeutic efficacy in triple-negative breast cancer and melanoma: synergistic effects of modulated electro-hyperthermia (mEHT) with NSAIDs especially COX-2 inhibition in in vivo models Mol. Oncol. (IF 6.6) Pub Date : 2024-01-12 Nino Giunashvili, Jeremiah Mbuotidem Thomas, Csaba András Schvarcz, Pedro Henrique Leroy Viana, Kenan Aloss, Syeda Mahak Zahra Bokhari, Zoltán Koós, Dániel Bócsi, Enikő Major, Andrea Balogh, Zoltán Benyó, Péter Hamar
-
New retinoblastoma (RB) drug delivery approaches: anti-tumor effect of atrial natriuretic peptide (ANP)-conjugated hyaluronic-acid-coated gold nanoparticles for intraocular treatment of chemoresistant RB Mol. Oncol. (IF 6.6) Pub Date : 2024-01-12 André Haase, Natalia Miroschnikov, Stefan Klein, Annika Doege, Nicole Dünker, Dario Van Meenen, Andreas Junker, Achim Göpferich, Paola Stephanie Apaolaza, Maike Anna Busch
-
Single extracellular vesicle surface protein-based blood assay identifies potential biomarkers for detection and screening of five cancers Mol. Oncol. (IF 6.6) Pub Date : 2024-01-09 Yuxin Min, Wenjiang Deng, Huangbo Yuan, Dongliang Zhu, Renjia Zhao, Pengyan Zhang, Jiangli Xue, Ziyu Yuan, Tiejun Zhang, Yanfeng Jiang, Kelin Xu, Di Wu, Yanling Cai, Chen Suo, Xingdong Chen
-
-
Reviewers Acknowledgement Mol. Oncol. (IF 6.6) Pub Date : 2024-01-04
The Editors of Molecular Oncology would like to thank all referees who have given their time and expertise to review articles submitted for publication in Volume 17. Molecular Oncology heavily relies on reviewers' careful assessment, constructive criticism, and timely response to ensure both quality and fast turnaround times. The names of these reviewers are listed below; we apologize if we have inadvertently
-
Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology Mol. Oncol. (IF 6.6) Pub Date : 2023-12-29 Javier A. Menendez, Elisabet Cuyàs, Jose Antonio Encinar, Travis Vander Steen, Sara Verdura, Àngela Llop-Hernández, Júlia López, Eila Serrano-Hervás, Sílvia Osuna, Begoña Martin-Castillo, Ruth Lupu
-
Building flexible and robust analysis frameworks for molecular subtyping of cancers Mol. Oncol. (IF 6.6) Pub Date : 2023-12-29 Christina Bligaard Pedersen, Benito Campos, Lasse Rene, Helene Scheel Wegener, Neeraja M. Krishnan, Binay Panda, Kristoffer Vitting-Seerup, Maria Rossing, Frederik Otzen Bagger, Lars Rønn Olsen